Article
EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.
Cancer biology & therapy - 1 Jan 2016
Que Dan, Xiao He, Zhao Baojian, Zhang Xu, Wang Qiushi, Xiao Hualiang, Wang Ge
Abstract excerpt
OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can effectively control non-small cell lung cancer (NSCLC). Therefore, EGFR mutations should be detected before lung cancer patients undergo EGFR-TKI therapy. This study assessed the feasibility and predictive value of EGFR mutations in peripheral blood samples. METHODS: EGFR mutations in exons 19 and 21 were analyzed in tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.